Lakeshore Hospital Unlisted Share Price
vs. prev. close ₹98
52W High
₹98
52W Low
₹96
Market cap
₹960 Cr
IPO stage
No DRHP filed
CIN
U85110KL1996PLC010260
Price History
52W High
₹98
52W Low
₹96
About Lakeshore Hospital Unlisted Share Price
A well-established, 30-year-old Kochi super-speciality hospital backed by the VPS Healthcare group, delivering audited FY26 profit growth of 35.7% on steady volume gains and declaring its highest-ever dividend, with management now guiding to an ambitious step-up in FY27 profitability.
Short Version :
Lakeshore Hospital and Research Centre Limited (VPS Lakeshore) is a Kochi-based multi-speciality super-speciality hospital, part of the UAE-headquartered VPS Healthcare group, marking its 30th year of operations in FY26. On a consolidated basis, Total Income grew 10.9% to Rs461.18 crore (FY25: Rs415.75 crore), while Profit After Tax grew a sharper 35.7% to Rs53.07 crore (FY25: Rs39.12 crore), reflecting margin expansion alongside steady volume growth. Disclosed EPS was Rs5.31 Basic and Diluted (FY25: Rs3.91) on face value Rs10. Closing equity grew to Rs455.70 crore (FY25: Rs422.24 crore), working out to BVPS of Rs45.57 (FY25: Rs42.22) and ROE of 11.65% (FY25: 9.27%) on a closing-equity basis. The Board has recommended a dividend of Rs2.50 per share (25%), the highest in the Company's history.
Why It Trades Where It Does :
The hospital delivered broad-based volume growth in FY26, inpatient discharges up 5% to 22,098, outpatient visits crossing 3.5 lakh, emergency admissions up roughly 40%, and international outpatient visits up about 15%, while simultaneously improving profitability, net margin rose from roughly 9.4% to 11.5% of total income. The year was also marked by clinical differentiation (India's first dedicated Centre for Complex Head and Neck Cancer, Asia's first nanoscopic ACL reconstruction) that supports premium positioning within Kerala's healthcare market. Management has guided to an ambitious FY27 target of Rs575 crore turnover and Rs120 crore PBT (against FY26's Rs71.42 crore), a roughly 68% PBT growth target that signals strong confidence but is also a steep bar for the business to clear.
Top Risk :
Long-running, multi-year tax litigation remains unresolved, with contingent liabilities across disputed Service Tax, VAT, and Income Tax demands spanning assessment years 2008-09 through 2022-23, totalling approximately Rs18.7 crore, plus a separate EPF dispute of Rs0.65 crore before the Kerala High Court.
Trade receivables grew sharply (consolidated: Rs56.80 crore from Rs33.93 crore, up ~67%), outpacing the 10.9% growth in Total Income, a working-capital trend worth monitoring even though the absolute scale remains modest relative to turnover.
Management's FY27 guidance is aggressive: a targeted ~68% jump in PBT (to Rs120 crore) on ~25% revenue growth implies a significant further margin expansion that may be difficult to sustain if cost pressures (especially the capex-heavy renovation programme) build up.
Rising capital expenditure on an aging campus: Property, Plant and Equipment additions nearly doubled to Rs35.46 crore (FY25: Rs22.69 crore) as the Company undertakes a phased renovation of OPDs, patient rooms, and ICUs, plus a planned multi-level car park, a sustained capex commitment funded largely from internal cash generation.
Geographic and single-facility concentration: the business is built around one super-speciality hospital campus in Kochi (plus referral clinics), with the only subsidiary now dissolved, meaning all operational risk sits within a single facility and the Kerala healthcare market.
Top Opportunities :
Profitability outpaced revenue growth, with PAT up 35.7% against 10.9% income growth, auditied and verified, pointing to improving operating leverage.
Highest-ever dividend declared (Rs2.50/share, 25%, ~Rs25 crore payout), signalling management and Board confidence in sustained cash generation.
Strong clinical differentiation and reputation: multiple India/Asia clinical firsts during the year (Head and Neck Cancer Centre, nanoscopic ACL reconstruction, AI-integrated laser treatment for piles/fistula/varicose veins) support premium positioning and patient trust.
Backing of the VPS Healthcare group (UAE-headquartered), a large regional healthcare platform, lending scale, brand, and potential access to capital and best practices.
Clean, unqualified audit opinion on both standalone and consolidated financial statements from long-tenured auditor Krishnamoorthy & Krishnamoorthy, with no fraud reported and an adequate, effectively operating internal financial controls framework.
Disclaimer :
Priveq.in is an informational platform for unlisted and pre-IPO shares, operated by Priveq Investech Private Limited (the named counterparty on transactions). Unlisted shares carry risks including illiquidity, valuation uncertainty, and limited regulatory disclosure. This page is informational only and does not constitute investment advice.
Company Details
Industry
Pharmaceuticals
Founded
1996
Headquarters
Kochi, Keralam, India
Min Lot Size
1
Face Value
₹10.00
Shares Outstanding
10,00,00,000
Regulatory Information
Corporate Identity Number (CIN)
U85110KL1996PLC010260
PAN Number
AAACL4923A
ISIN
INE01TI01010
Key Valuation Ratios
Valuation
Market Cap
₹960.00 Cr
P/E Ratio
18.09×
P/S Ratio
2.12×
P/B Ratio
2.11×
EV / EBITDA
9.22×
Returns & Per Share
ROE
11.64%
EPS
₹5.31
Book Value / Share
₹45.57
Solvency
Debt / Equity
0.00×
Interest Coverage
199.36×
Company Fundamentals
As of FY2026 Annual · updated 28 Oct 2026Gross Profit
₹452.74 Cr
EBITDA
₹99.15 Cr
Revenue Growth
11.10%
Profit Margin
11.72%
Performance Trends
5 annual periods · derived from filed statements
Revenue
₹ Cr
Net Profit
₹ Cr · losses in red
Earnings Per Share
₹ per share
Return on Equity
ROE %
Return on Capital Employed
ROCE %
Debt-to-Equity
0.00×
EBITDA Margin
21.90%
Interest Coverage
199.36×
Financial Statements
| Line item | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
| Total Income | |||||
| Revenue from operationsDisclosed | 358.59₹ Crore | 419.18₹ Crore | 396.22₹ Crore | 407.52₹ Crore | 452.74₹ Crore |
| Other incomeDisclosed | 3.07₹ Crore | 5.36₹ Crore | 6.67₹ Crore | 8.23₹ Crore | 8.44₹ Crore |
| Total IncomeDerived | 361.66₹ Crore | 424.54₹ Crore | 402.89₹ Crore | 415.75₹ Crore | 461.18₹ Crore |
| Expenses | |||||
| Cost of goods soldDisclosed | 0₹ Crore | 0₹ Crore | 0₹ Crore | 0₹ Crore | 0₹ Crore |
| Purchases of stock-in-tradeDisclosed | 102.51₹ Crore | 111.7₹ Crore | 111.32₹ Crore | 116.96₹ Crore | 128.58₹ Crore |
| Changes in inventoriesDisclosed | -1.86₹ Crore | -1.66₹ Crore | 2.01₹ Crore | -21₹ Lakh | 37₹ Lakh |
| Employee benefits expenseDisclosed | 62.82₹ Crore | 63.84₹ Crore | 75.06₹ Crore | 79.37₹ Crore | 83.96₹ Crore |
| Finance costsDisclosed | 2.57₹ Crore | 2.11₹ Crore | 93₹ Lakh | 33₹ Lakh | 36₹ Lakh |
| Depreciation and amortization expenseDisclosed | 21.46₹ Crore | 22.69₹ Crore | 23.7₹ Crore | 26.05₹ Crore | 27.38₹ Crore |
| Manufacturing expensesDisclosed | 0₹ Crore | 0₹ Crore | 0₹ Crore | 0₹ Crore | 0₹ Crore |
| Operating expensesDisclosed | 0₹ Crore | 0₹ Crore | 0₹ Crore | 0₹ Crore | 0₹ Crore |
| Other expensesDisclosed | 113.37₹ Crore | 143.44₹ Crore | 134.87₹ Crore | 140.51₹ Crore | 149.12₹ Crore |
| Total ExpensesDerived | 300.87₹ Crore | 342.12₹ Crore | 347.89₹ Crore | 363.01₹ Crore | 389.77₹ Crore |
| Profit | |||||
| Exceptional itemsDisclosed | 0₹ Crore | 0₹ Crore | 0₹ Crore | 0₹ Crore | 0₹ Crore |
| Profit before taxDerived | 60.79₹ Crore | 82.42₹ Crore | 55₹ Crore | 52.74₹ Crore | 71.41₹ Crore |
| Current tax expenseDisclosed | 15.21₹ Crore | 26.61₹ Crore | 13.52₹ Crore | 14.1₹ Crore | 16.82₹ Crore |
| Deferred tax expenseDisclosed | 2.61₹ Crore | -1.88₹ Crore | -2.41₹ Crore | -49₹ Lakh | 1.51₹ Crore |
| Tax expenseDisclosed | 17.9₹ Crore | 24.9₹ Crore | 11.13₹ Crore | 13.62₹ Crore | 18.35₹ Crore |
| Profit After TaxDerived | 42.89₹ Crore | 57.52₹ Crore | 43.87₹ Crore | 39.12₹ Crore | 53.06₹ Crore |
| Other comprehensive incomeDisclosed | 0₹ Crore | 0₹ Crore | 0₹ Crore | 0₹ Crore | 0₹ Crore |
| Total Comprehensive IncomeDerived | 42.89₹ Crore | 57.52₹ Crore | 43.87₹ Crore | 39.12₹ Crore | 53.06₹ Crore |
Express buy interest
No commitment — the desk will reach out
Current Price
₹96Secure & Verified Transaction
Unlisted shares are illiquid and carry higher market risks. Please read the Risk Disclosure before investing.
Talk to a Specialist
Get expert guidance on this investment
About Lakeshore Hospital Unlisted Share Price unlisted shares
Indicative · updated dailyLakeshore Hospital Unlisted Share Price unlisted share price today
Lakeshore Hospital Unlisted Share Price unlisted share price today is ₹96 as of 12 November 2026.
Lakeshore Hospital Unlisted Share Price — frequently asked questions
- What is the grey market price for Lakeshore Hospital Unlisted Share Price?
No IPO is currently announced for Lakeshore Hospital Unlisted Share Price, so no grey market exists; the price above reflects Priveq's own desk valuation.
- Has Lakeshore Hospital Unlisted Share Price filed for an IPO, and when might it list?
Lakeshore Hospital Unlisted Share Price has not filed a draft red herring prospectus, so no IPO is currently announced and no listing date has been set.
- How does Lakeshore Hospital Unlisted Share Price compare to its listed peers?
There is no closely comparable listed company for Lakeshore Hospital Unlisted Share Price in India today.
- Is Lakeshore Hospital Unlisted Share Price on the SME or Mainboard IPO track?
Lakeshore Hospital Unlisted Share Price has not filed a draft red herring prospectus, so no IPO track is set yet.
- What is Lakeshore Hospital Unlisted Share Price's CIN and registered office?
Lakeshore Hospital Unlisted Share Price's Corporate Identity Number is U85110KL1996PLC010260, registered at Kochi, Keralam, India.
- What is Lakeshore Hospital Unlisted Share Price's market capitalisation?
Lakeshore Hospital Unlisted Share Price's market capitalisation is approximately ₹960 crore, based on its current unlisted share price.
More in Pharmaceuticals
All Pharmaceuticals →- Sigachi Laboratories Limited Unlisted Shares₹52+0.0%
- East India Pharmaceutical Works Limited₹79
- Veeda Clinical Research Limited₹428+0.0%
- Inox Air Products Limited₹1,600
- Inox Leasing and Finance Limited₹19,250+2.4%
- Incred Capital Financial Services Limited₹4,850
- India Gold Metaverse Limited₹25.25
- Ekkaa Electronics (India) Ltd.₹500
Buying, selling and holding unlisted shares
Applies to every company on Priveq- How do I buy Lakeshore Hospital Unlisted Share Price unlisted shares?
Priveq Investech Private Limited is the named counterparty on every transaction. To buy Lakeshore Hospital Unlisted Share Price unlisted shares: complete KYC once (PAN, Aadhaar, bank details, and demat account information — SEBI-compliant, typically approved within 24 hours), then submit your order through your Priveq dashboard specifying quantity. Our team confirms price and payment details with you directly. Once payment is confirmed, Lakeshore Hospital Unlisted Share Price shares are transferred off-market straight to your demat account, with no pooling and no middlemen.
- How do I sell Lakeshore Hospital Unlisted Share Price unlisted shares?
Submit an Express Sell Interest for Lakeshore Hospital Unlisted Share Price through your Priveq dashboard, specifying quantity, the same way a buy order is placed. Priveq quotes you a bid price, which may differ from the live Buy price shown to buyers, since unlisted-share pricing works on a bid-ask basis rather than a single quote. Once you accept, you'll need to provide your Client Master List (CML), a cancelled cheque or bank details, and PAN. If you hold shares with CDSL, transfer can also be completed digitally via CDSL Easiest. You transfer Lakeshore Hospital Unlisted Share Price shares to Priveq first, and payment follows once the transfer is confirmed received, typically the same day, T+1, or occasionally T+2, communicated to you directly. For sizeable transactions worth crores of rupees, an escrow arrangement can be used instead, at the sole consent of both parties.
- What is the minimum investment for Lakeshore Hospital Unlisted Share Price unlisted shares?
Minimum investment varies by company and is shown as the Min Investment figure on this page. Lakeshore Hospital Unlisted Share Price's minimum is ₹96.
- Is there a maximum investment limit?
There's no fixed maximum investment limit for Lakeshore Hospital Unlisted Share Price unlisted shares. For sizeable transactions worth crores of rupees, an escrow arrangement can be used at the sole consent of both parties, the same mechanism available on the sell side.
- Is buying Lakeshore Hospital Unlisted Share Price unlisted shares legal in India?
Yes. Buying and selling unlisted shares in India is legal and is subject to relevant SEBI regulations, including the mandatory lock-in period after listing, stamp duty, and depository participant charges on each transaction. Priveq's own KYC process is built to be SEBI-compliant.
- What is the lock-in period for Lakeshore Hospital Unlisted Share Price unlisted shares?
Lakeshore Hospital Unlisted Share Price has not filed a DRHP yet, so no listing date or lock-in period applies at this stage. Once an IPO is filed, this answer updates to reflect the applicable SME or Mainboard lock-in.
- What happens if Lakeshore Hospital Unlisted Share Price's IPO is delayed or withdrawn?
If an IPO is delayed, shares remain unlisted and continue to trade on the desk at Priveq's indicative price, with no lock-in in effect until an actual listing happens. If a company formally withdraws its DRHP, the same applies: shares stay unlisted, with no lock-in period until and unless a fresh IPO process begins.
- How are capital gains on Lakeshore Hospital Unlisted Share Price unlisted shares taxed?
If you sell unlisted shares, including Lakeshore Hospital Unlisted Share Price, within 24 months of purchase, the gain is taxed as short-term capital gain at your applicable income tax slab rate. Beyond 24 months, it is taxed as long-term capital gain at 12.5 percent, without indexation benefit, under the rules effective from 23 July 2024. If Lakeshore Hospital Unlisted Share Price lists and you sell after listing, the applicable tax treatment shifts to listed-security rates, with the holding period still measured from your original unlisted purchase date. This is general information, not tax advice; investors should confirm their specific position with a tax advisor.
- Can NRIs invest in Lakeshore Hospital Unlisted Share Price unlisted shares?
Yes, on a non-repatriable basis. NRIs can invest using funds from an NRO account; sale proceeds stay within India unless repatriated separately under RBI's own limits. Priveq does not currently support repatriable investment (NRE/FCNR-funded), which would require the investee company to file additional RBI paperwork as foreign direct investment.
- Does Priveq charge a platform fee on top of the share price?
No. The price quoted to you is all-in; there is no separate platform fee or brokerage added on top.
- How does Priveq determine the desk price for Lakeshore Hospital Unlisted Share Price?
Priveq's desk price reflects several inputs together, not a single formula: the seller's ask price at the time, current demand and supply on the platform for Lakeshore Hospital Unlisted Share Price specifically, broader sentiment in the unlisted and pre-IPO market, how Lakeshore Hospital Unlisted Share Price's sector and listed peers are trading, the company's own recent financial performance and IPO-stage developments, and recent transaction history where deals have actually closed.
Because unlisted shares trade over the counter rather than on an exchange, this price is indicative, not a continuously live quoted market price, and the actual deal price is confirmed with you directly before a transaction closes.
- Is Priveq SEBI-registered? Does it give investment advice?
Priveq is not a SEBI-registered stock exchange and not a SEBI-registered investment adviser. Priveq Investech Private Limited operates Priveq.in as a research and information platform for unlisted and pre-IPO shares, and is the named counterparty on transactions executed through the platform. Nothing on this page is investment advice; it's information to help you evaluate a company and decide for yourself.
- Am I eligible to invest through Priveq if I'm not an HNI?
Yes. Priveq isn't a stock exchange with membership restrictions, and investing isn't limited to HNIs. Depending on the company, entry points can start as low as ₹20,000, though the minimum for any specific company is shown as the Min Investment figure on its page.
- What documents do I receive after buying unlisted shares?
You receive an email acknowledging and confirming your order, along with a deal note or invoice recording the transaction details.
- What happens to my shares or money if a deal falls through?
Because Priveq is the direct counterparty on every transaction rather than just connecting a buyer and seller, this risk sits with Priveq, not with you. If a deal falls through after you've committed funds or shares, they remain safe, and Priveq guarantees a refund.